Bristol-Myers Squibb reports third quarter results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2016 which were highlighted by strong sales and operating performance, and continued growth for key products including Opdivo and Eliquis . The company raised full-year guidance for 2016 and provided guidance expectations for 2017,
Bayer shows strong performance
- Details
- Category: Bayer
The Bayer Group remained on a path of growth in the third quarter of 2016 and took a major strategic step forward with the agreed acquisition of Monsanto. "The announcement that we had reached agreement to acquire Monsanto is a major strategic milestone for Bayer. We will be creating a global leader in agriculture and, at the same time, reinforcing our leadership position as a Life Science company," said Bayer Management Board Chairman Werner Baumann.
Amgen builds its digital health capabilities through investment in leading digital health incubator
- Details
- Category: Amgen
Amgen (Europe) GmbH, an affiliate of Amgen Inc. (NASDAQ:AMGN) (collectively, "Amgen") today announced an investment in eHealth Ventures, an Israel-based digital health incubator. The investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery, and recognizes the importance of Israel as a source of innovation in eHealth and digital technologies.
Novartis delivered solid third quarter
- Details
- Category: Novartis
Net sales were USD 12.1 billion in the third quarter, as volume growth of 5 percentage points was more than offset by the negative impact of generic competition and pricing. Growth Products contributed USD 4.3 billion or 36% of net sales, up 20% (USD) over the prior-year quarter. Operating income was USD 2.3 billion. Core adjustments amounted to USD 1.1 billion (2015: USD 1.3 billion), broadly in line with the prior-year quarter.
Get your startup to the next level
- Details
- Category: Merck Group
The Merck Accelerator is looking for startups with the potential to reshape entire industries and make people's lives richer. The focus is on startups in the fields of healthcare, life science and performance materials - with a digital perspective. Do you have plans to internationalize your business? Are you ready to get your start-up to the next level?
Roche delivers good sales growth in the first nine months of 2016
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that Group sales increased 4% to CHF 37.5 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 29.1 billion, driven by demand for breast cancer medicines Perjeta and Herceptin as well as for Actemra/RoActemra for rheumatoid arthritis.
Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced an award of a grant from the Bill & Melinda Gates Foundation to conduct a Phase 1/2 clinical trial of Pfizer's vaccine candidate against group B Streptococcus(group B strep or GBS) infection, a leading cause of neonatal sepsis, a serious life-threatening blood infection.
More Pharma News ...
- FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
- Bristol-Myers Squibb Foundation joins White House Cancer Moonshot
- Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community
- Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme
- Merck announces recipients of third annual €1 million 'Grant for Oncology Innovation' award
- AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US
- FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC